{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:00:15Z","timestamp":1783702815563,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12640-022-00498-3","type":"journal-article","created":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T07:38:30Z","timestamp":1648885110000},"page":"564-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Protective Effect of CP690550 in MPTP-Induced Parkinson\u2019s Like Behavioural, Biochemical and Histological Alterations in Mice"],"prefix":"10.1007","volume":"40","author":[{"given":"Abdulrahman","family":"Alshammari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metab","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A.","family":"Albekairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer H.","family":"Albekairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar O.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Yeapuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9021-6547","authenticated-orcid":false,"given":"Sanjiv","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,2]]},"reference":[{"key":"498_CR1","first-page":"1321","volume":"337","author":"YJTL Agid","year":"1991","unstructured":"Agid YJTL (1991) Parkinson\u2019s Disease: Pathophysiology 337:1321\u20131324","journal-title":"Parkinson\u2019s Disease: Pathophysiology"},{"key":"498_CR2","doi-asserted-by":"crossref","unstructured":"Aguirre JA, Leo G, Cueto R, Andbjer B, Naylor A, Medhurst AD, Agnati LF, Fuxe K\u00a0(2008)\u00a0The novel cyclooxygenase-2 inhibitor GW637185X protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity.\u00a0Neuroreport\u00a019:657\u2013660","DOI":"10.1097\/WNR.0b013e3282fb7898"},{"key":"498_CR3","doi-asserted-by":"crossref","unstructured":"Appel SH, Beers DR, Henkel JS (2010)\u00a0T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol 31(1):7\u201317","DOI":"10.1016\/j.it.2009.09.003"},{"key":"498_CR4","doi-asserted-by":"crossref","unstructured":"Bartels AL, Leenders KL\u00a0(2007) Neuroinflammation in the pathophysiology of Parkinson\u2019s disease: evidence from animal models to human in vivo studies with [11C]\u2010PK11195 PET\u00a022:1852\u20131856","DOI":"10.1002\/mds.21552"},{"key":"498_CR5","first-page":"245","volume":"7","author":"F Benetti","year":"2012","unstructured":"Benetti F (2012) Gustincich S and Legname GJEoodd. Gene Expression Profiling and Therapeutic Interventions in Neurodegenerative Diseases: a Comprehensive Study on Potentiality and Limits 7:245\u2013259","journal-title":"Gene Expression Profiling and Therapeutic Interventions in Neurodegenerative Diseases: a Comprehensive Study on Potentiality and Limits"},{"key":"498_CR6","doi-asserted-by":"crossref","unstructured":"Berman SB, Hastings TG (1999)\u00a0Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson\u2019s disease. J Neurochem 73(3):1127\u20131137","DOI":"10.1046\/j.1471-4159.1999.0731127.x"},{"key":"498_CR7","doi-asserted-by":"crossref","unstructured":"Cao S, Theodore S, Standaert DG (2010)\u00a0Fc\u03b3 receptors are required for NF-\u03baB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol neurodegener 5(1):1\u20132","DOI":"10.1186\/1750-1326-5-42"},{"key":"498_CR8","first-page":"694","volume":"14","author":"P Chakrabarty","year":"2011","unstructured":"Chakrabarty P, Ceballos-Diaz C, Lin WL, Beccard A, Jansen-West K, McFarland NR, Janus C, Dickson D, Das P, Golde TE (2011) Interferon-\u03b3 Induces Progressive Nigrostriatal Degeneration and Basal Ganglia Calcification 14:694\u2013696","journal-title":"Interferon-\u03b3 Induces Progressive Nigrostriatal Degeneration and Basal Ganglia Calcification"},{"key":"498_CR9","first-page":"90","volume":"167","author":"H Chen","year":"2008","unstructured":"Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A (2008)\u00a0Peripheral Inflammatory Biomarkers and Risk of Parkinson\u2019s Disease 167:90\u201395","journal-title":"Peripheral Inflammatory Biomarkers and Risk of Parkinson\u2019s Disease"},{"key":"498_CR10","first-page":"963","volume":"60","author":"YC Chung","year":"2011","unstructured":"Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, Bok E, Jin M, Park ES, Yoon SH (2011)\u00a0Fluoxetine Prevents MPTP-Induced Loss of Dopaminergic Neurons by Inhibiting Microglial Activation 60:963\u2013974","journal-title":"Fluoxetine Prevents MPTP-Induced Loss of Dopaminergic Neurons by Inhibiting Microglial Activation"},{"key":"498_CR11","first-page":"180","volume":"36","author":"Y Dong","year":"2001","unstructured":"Dong Y, Benveniste EN\u00a0(2001) Immune Function of Astrocytes 36:180\u2013190","journal-title":"Immune Function of Astrocytes"},{"key":"498_CR12","doi-asserted-by":"crossref","unstructured":"Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, Prakash C (2014)\u00a0The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.\u00a0Drug Metab Dispos\u00a042(4):759\u2013773","DOI":"10.1124\/dmd.113.054940"},{"key":"498_CR13","doi-asserted-by":"crossref","unstructured":"Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, Wenning GK, Stefanova N (2013)\u00a0Toll\u2010like receptor 4 is required for \u03b1\u2010synuclein dependent activation of microglia and astroglia. Glia 61(3):349\u2013360","DOI":"10.1002\/glia.22437"},{"key":"498_CR14","first-page":"1009","volume":"81","author":"AE Frakes","year":"2014","unstructured":"Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, Ladner KJ, Bevan AK, Foust KD, Godbout JPJN (2014) Microglia Induce Motor Neuron Death via the Classical NF-\u039ab Pathway in Amyotrophic Lateral Sclerosis 81:1009\u20131023","journal-title":"Microglia Induce Motor Neuron Death via the Classical NF-\u039ab Pathway in Amyotrophic Lateral Sclerosis"},{"key":"498_CR15","first-page":"392","volume":"28","author":"N Funk","year":"2013","unstructured":"Funk N, Wieghofer P, Grimm S, Schaefer R, B\u00fchring HJ, Gasser T, Biskup SJMD (2013) Characterization of Peripheral Hematopoietic Stem Cells and Monocytes in Parkinson\u2019s Disease 28:392\u2013395","journal-title":"Characterization of Peripheral Hematopoietic Stem Cells and Monocytes in Parkinson\u2019s Disease"},{"key":"498_CR16","first-page":"1285","volume":"81","author":"HM Gao","year":"2002","unstructured":"Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002)\u00a0Microglial Activation-Mediated Delayed and Progressive Degeneration of Rat Nigral Dopaminergic Neurons: Relevance to Parkinson\u2019s Disease 81:1285\u20131297","journal-title":"Microglial Activation-Mediated Delayed and Progressive Degeneration of Rat Nigral Dopaminergic Neurons: Relevance to Parkinson\u2019s Disease"},{"key":"498_CR17","first-page":"273","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ (2009) Janus Kinases in Immune Cell Signaling 228:273\u2013287","journal-title":"Janus Kinases in Immune Cell Signaling"},{"key":"498_CR18","first-page":"18754","volume":"104","author":"A Ghosh","year":"2007","unstructured":"Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K (2007)\u00a0Selective Inhibition of NF-\u039ab Activation Prevents Dopaminergic Neuronal Loss in a Mouse Model of Parkinson\u2019s Disease 104:18754\u201318759","journal-title":"Selective Inhibition of NF-\u039ab Activation Prevents Dopaminergic Neuronal Loss in a Mouse Model of Parkinson\u2019s Disease"},{"key":"498_CR19","doi-asserted-by":"crossref","unstructured":"Gray GK, McFarland BC, Nozell SE, Benveniste EN (2014)\u00a0NF-\u03baB and STAT3 in glioblastoma: therapeutic targets coming of age.\u00a0Expert Rev Neurother\u00a014(11):1293\u20131306","DOI":"10.1586\/14737175.2014.964211"},{"key":"498_CR20","doi-asserted-by":"crossref","unstructured":"Gupta A, Kumar A, Kulkarni SK (2010)\u00a0Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidence. Inflammopharmacology 18(5):223\u2013232","DOI":"10.1007\/s10787-010-0052-6"},{"key":"498_CR21","first-page":"214","volume":"991","author":"E Hirsch","year":"2003","unstructured":"Hirsch E, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PJDP (2003) The Role of Dial Reaction and Inflammation in Parkinson\u2019s Disease 991:214\u2013228","journal-title":"The Role of Dial Reaction and Inflammation in Parkinson\u2019s Disease"},{"key":"498_CR22","first-page":"1375","volume":"100","author":"RL Hunter","year":"2007","unstructured":"Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G (2007)\u00a0Inflammation Induces Mitochondrial Dysfunction and Dopaminergic Neurodegeneration in the Nigrostriatal System 100:1375\u20131386","journal-title":"Inflammation Induces Mitochondrial Dysfunction and Dopaminergic Neurodegeneration in the Nigrostriatal System"},{"key":"498_CR23","doi-asserted-by":"crossref","unstructured":"Kalonia H, Kumar P, Kumar A, Nehru B (2009)\u00a0Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. Inflammopharmacology 17(4):211\u2013219","DOI":"10.1007\/s10787-009-0012-1"},{"key":"498_CR24","first-page":"493","volume":"3","author":"GT Kannarkat","year":"2013","unstructured":"Kannarkat GT, Boss JM, Tansey MG (2013)\u00a0The Role of Innate and Adaptive Immunity in Parkinson\u2019s Disease 3:493\u2013514","journal-title":"The Role of Innate and Adaptive Immunity in Parkinson\u2019s Disease"},{"key":"498_CR25","doi-asserted-by":"crossref","unstructured":"Kim YS, Joh TH (2006)\u00a0Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease.\u00a0Exp Mol Med\u00a038(4):333\u2013347","DOI":"10.1038\/emm.2006.40"},{"key":"498_CR26","doi-asserted-by":"crossref","unstructured":"Migita K, Miyashita T, Izumi Y, Koga T, Komori A, Maeda Y, Jiuchi Y, Aiba Y, Yamasaki S, Kawakami A, Nakamura M (2011)\u00a0Inhibitory effects of the JAK inhibitor CP690, 550 on human CD4+ T lymphocyte cytokine production. BMC immunol 12(1):1\u20130","DOI":"10.1186\/1471-2172-12-51"},{"key":"498_CR27","first-page":"477","volume":"28","author":"JJ O\u2019Shea","year":"2008","unstructured":"O'Shea JJ, Murray PJ\u00a0(2008) Cytokine Signaling Modules in Inflammatory Responses 28:477\u2013487","journal-title":"Cytokine Signaling Modules in Inflammatory Responses"},{"key":"498_CR28","first-page":"311","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M (2015) McInnes IB and Laurence AJArom. The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention 66:311\u2013328","journal-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention"},{"key":"498_CR29","doi-asserted-by":"crossref","unstructured":"O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC (2007)\u00a0Cytokine receptor signaling through the Jak\u2013Stat\u2013Socs pathway in disease. Mol immunol 44(10):2497\u2013506","DOI":"10.1016\/j.molimm.2006.11.025"},{"key":"498_CR30","doi-asserted-by":"crossref","unstructured":"O\u2019shea JJ (2004)\u00a0Targeting the Jak\/STAT pathway for immunosuppression. Annals of the rheumatic diseases 63(suppl 2):ii67\u201371","DOI":"10.1136\/ard.2004.028290"},{"key":"498_CR31","doi-asserted-by":"crossref","unstructured":"Pattison MJ, MacKenzie KF, Arthur JS (2012) Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10\u2013mediated feedback. The J Immunol 189(6):2784\u20132792","DOI":"10.4049\/jimmunol.1200310"},{"key":"498_CR32","doi-asserted-by":"crossref","unstructured":"Shuai K, Liu B (2003)\u00a0Regulation of JAK\u2013STAT signalling in the immune system. Nat Rev Immunol 3(11):900\u2013911","DOI":"10.1038\/nri1226"},{"key":"498_CR33","doi-asserted-by":"crossref","unstructured":"Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, Valdez H, Langley RG, Harness J, Menter A, Papp K (2013)\u00a0Effect of tofacitinib, a J anus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 169(5):992\u2013999","DOI":"10.1111\/bjd.12517"},{"key":"498_CR34","doi-asserted-by":"crossref","unstructured":"Yarilina A, Xu K, Chan C, Ivashkiv LB (2012) Regulation of inflammatory responses in tumor necrosis factor\u2013activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis & Rheumatism 64(12):3856\u20133866","DOI":"10.1002\/art.37691"},{"key":"498_CR35","doi-asserted-by":"crossref","unstructured":"Yasuda T, Nakata Y, Mochizuki H (2003) \u03b1-Synuclein and neuronal cell death. Mol Neurobiol 47(2):466\u2013483","DOI":"10.1007\/s12035-012-8327-0"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-022-00498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12640-022-00498-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-022-00498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T05:02:43Z","timestamp":1650690163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12640-022-00498-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1007\/s12640-022-00498-3","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}